Solesence Inc is a health-oriented, science-driven company, focused on various skin health, beauty and wellness markets. Its primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection enabled by proprietary Active Pharmaceutical Ingredients, which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products. Additionally, it continues to sell products in legacy markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications. The company operates as a single business segment.
Last trade$1.68
Day change+$0.08 (+5.00%)
Day range$1.52 – $1.87
Volume562,619
Market cap$113M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$113.04M
Price / earnings
41.09×
Price / book
6.75×
Price / sales
1.86×
EV / sales
1.95×
EV / EBITDA
24.54×
Profitability
Earnings per share
$0.04
Return on assets
6.19%
Return on equity
16.42%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.44×
Current ratio
1.73×
Quick ratio
0.87×
Cash ratio
0.09×
Cash flow
Price / cash flow
11.03×
Price / free cash flow
11.54×
Free cash flow
$9.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SLSN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Revenue
$20.16M
$15.33M
$12.96M
$12.48M
$14.6M
$20.36M
Cost of revenue
$12.24M
$10.68M
$9.79M
$8.94M
$11.12M
$13.83M
Gross profit
$7.93M
$4.65M
$3.17M
$3.54M
$3.47M
$6.53M
Selling, general and administrative
$2.81M
$3.68M
$2.8M
$2.21M
$3.07M
$3.01M
Research and development
$1.08M
$947K
$1.04M
$1.04M
$1.08M
$955K
Total operating expenses
$3.89M
$4.63M
$3.84M
$3.25M
$4.15M
$3.97M
Operating income
$4.04M
$23K
-$674K
$296K
-$677K
$2.56M
Interest expense
-$258K
-$279K
-$263K
-$328K
-$339K
-$87K
Income before taxes
$3.89M
-$256K
-$936K
-$44K
-$1.02M
$3.71M
Income taxes
$219K
$0
$0
-$317K
$0
$390K
Net income
$3.67M
-$256K
-$936K
$273K
-$1.02M
$3.32M
Net income attributable to common shareholders
$3.67M
-$256K
-$936K
$273K
-$1.02M
$3.32M
EBITDA
$4.35M
$346K
-$361K
$517K
-$452K
$2.79M
Basic earnings per share
$0.05
$0.00
-$0.01
$0.00
-$0.01
$0.05
Diluted earnings per share
$0.05
$0.00
-$0.01
$0.00
-$0.01
$0.05
Recent news
Company coverage with links to the original publishers.
Solésence, Inc. (Nasdaq: SLSN) has been named Contract Manufacturing Partner of the Year at the 2026 Cosmetics Business Innovation Awards by HPCi Media. The award recognizes the company's excellence in client satisfaction, innovation, product development, reliability, and speed-to-market. This marks the company's 12th industry award since 2022, reflecting its leadership in scientifically-driven health care solutions across beauty and life science categories.
Solésence, Inc. announced its support for a landmark UK report calling for a national UV safety strategy to combat ultraviolet radiation exposure. The report, led by the UK's APPG for Beauty, Hair & Wellbeing, includes 29 recommendations to shift public perception of UV protection and increase access to protective products. With melanoma cases projected to rise 9% by 2038, the report advocates for sustained government-led campaigns similar to Australia's successful 'Slip, Slop, Slap!' initiative.
Solésence reported a challenging Q3 2025 with decreased revenue and net loss, implementing strategic leadership changes and operational restructuring to drive future growth and efficiency.
Solésence has appointed Yoana Dvorzsak as Vice President of Innovation and Product Integrity, unifying research, development, regulatory, and quality operations to drive innovation and operational excellence. Dvorzsak was also recognized as a 2025 CEW Innovator Honoree.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.